|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Molecular Targeted Cancer Therapies - More Pipeline Activity, Less Product Differentiation
Datamonitor, Nov 2008, Pages: 431
Approaches to cancer treatment continue to incorporate molecular targeted therapies into standard treatment regimens. With an increasing number of candidates gaining approval, and with a dynamic developmental pipeline, further clinical, commercial and strategic challenges are continuing to emerge.
Scope
- Research and analysis of the MTT pipeline with in-depth clinical and commercial assessment of Phase III candidates
- Seven major pharmaceutical market sales forecasts to 2017 for key pipeline candidates incorporating product specific assumptions and events
- Segmentation and examination of product pipeline by developmental phase, class, mode of action, indication and developer
- Insight and analysis of market potential including commercial opportunity, commonalities across cancers and discussion of unmet needs
Highlights of this title
373 different pipeline candidates have been identified of which 38 are in late-phase development. These identified candidates have a forecast sales potential of up to $7.31 billion in the seven major pharmaceutical markets by 2017.
Agents holding the greatest commercial potential include Afinitor (everolimus; Novartis), Omnitarg (pertuzumab; Genentech/Roche), Brivanib (BMS-582664; Bristol-Myers Squibb) and aflibercept (VEGF-Trap; Sanofi-Aventis).
The big four tumor typesnon-small cell lung cancer (NSCLC), breast cancer, colorectal cancer and prostate cancercontinue to attract the main attention from MTT developers. However, niche tumor types with lower bars to market entry can still offer high rewards for effective candidates.
Key reasons to purchase this title
- Acquire a detailed appreciation and impartial perspective of the entire molecular targeted therapies developmental pipeline
- Identify the key products in late-phase development based on sales forecasts to 2017 and The drug assessment methodology
- Assess the shifting oncology market dynamic and how future treatment of many cancers will incorporate pipeline products
Customers who bought this item also bought
Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor types
Pipeline Insight: Non-Small Cell Lung Cancer - Pipeline Set To Offer Only Modest Improvements
Prospects for the Phase III Bapineuzumab Trial
Pipeline Insight: Cancer Overview - Gastrointestinal, Skin, Sarcomas
Gastric Cancer - Targeted Therapies Compete for First-to-Market Status
Pipeline Insight: Cancer Overview - Increasing Diversity Offers Both High Risk and Reward
Pipeline Insight: Breast Cancer - Recent Approvals Increase Pressure On Pipeline Candidates
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies - More Drugs on the Market, More Targets in the Pipeline
Stakeholder Opinions: Small Cell Lung Cancer and Malignant Mesothelioma - Limited R&D Activity Provides Opportunity for Early-Phase Pipeline Drugs
Cell Therapy Clinical Trial Analysis
Stakeholder Insight: Renal Cancer - Targeted therapies rapidly take hold of market
Cancer Drug Resistance
|
|
|
|
